Clinical Dialogue: Dyslipidemia Management: Opportunities to Improve Patient Care
Cardiovascular disease (CVD) is the leading cause of death in the United States (U.S.), affecting approximately 92 million American adults. Estimates indicate that 43.9% of the U.S. population will have some form of CVD by 2030. A large number of epidemiologic
studies have shown that the risk of CVD rises significantly with increasing levels of low-density lipoprotein cholesterol (LDL-C). Correspondingly, decreases in LDL-C levels reduce the risk of nonfatal CV events as well as mortality over a wide range
of baseline risk and LDL-C levels. Accordingly, LDL-C has largely replaced total cholesterol as both a risk marker and the main target of treatment for dyslipidemia. The management of elevated LDL-C is, therefore, fundamental in the primary and secondary
prevention of CVD and related adverse outcomes. PAs have a critical role in the management of patients with dyslipidemia. This program will appeal to various learning styles and allow participants to reinforce their knowledge and acquire new skills
that can immediately be applied to clinical practice.
At the conclusion of this activity, the PA should be better able to:
- Evaluate available options for LDL-C management to identify appropriate therapy
- Implement guideline-based recommendations for both risk evaluation and management of dyslipidemia
- Integrate patient specific risk assessment and clinical considerations into the decision-making process
- Create integrated patient care plans to optimize medication adherence and appreciate how less frequent dosing schedules may be associated with increased medication adherence
Acknowledgement of Commercial Support
Supported by an independent educational grant from Amgen, Inc.